The five startup companies are focused on molecular diagnostics, precision oncology, personalized medicine, and more.
The funding will support efforts to convert PGDx's technology, including both tissue and liquid biopsy tests, for dissemination as regulated IVD kits.
The new hardware expands Garvan's current system so that it can better support large-scale whole-genome and single-cell sequencing initiatives.
The Genome Canada program will encourage the formation of private-public partnerships to develop gene-based technologies for healthcare and agriculture.
Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
Benchmark led a new investment round in digital lab notebook maker Benchling, which claims 500 percent year-over-year growth in annual recurring revenue.
Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.
Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.
The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.
The New York Times writes that natural history museums are helping round out genetic studies with older specimens.
In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.